Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABA 101

Next Previous
X
Search
Drug Profile

ABA 101

Alternative Names: ABA-101

Latest Information Update: 06 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abata Therapeutics
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 23 Aug 2024 Abata Therapeutics plans a phase I trial for Multiple sclerosis in September 2024 (Parenteral) (NCT06566261)
  • 22 Aug 2024 ABA 101 receives Fast Track designation for Multiple sclerosis [Parenteral] in USA
  • 09 Jul 2024 US FDA approves IND application for ABA 101 in Multiple sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top